1 paper3 findings
Nonlymphoma mortality
upin humans1
Lymphoma Epidemiology of Outcomes Comorbidity Index predicts nonlymphoma mortality in humans (11%, 13%, and 26% for LCI 0, 1, and 2+).
“higher 2-year nonlymphoma mortality (11%, 13%, and 26% for LCI 0, 1, and 2+)”
HumansLarge B-cell lymphoma2 yearsn = 539
Other illnesses linked to poorer lymphoma survival at 80 and over
Clinical lymphoma, myeloma & leukemia23 Sep 2026
Event-free survival
downin humans1HR 1.78
Lymphoma Epidemiology of Outcomes Comorbidity Index predicts event-free survival in humans (LCI 2+ versus 0: HR 1.78, 95% CI 1.33–2.38).
“EFS (LCI 1 vs. 0: HR = 1.37 [1.00-1.87]; LCI 2+ vs. 0: HR = 1.78 [1.33-2.38])”
HumansLarge B-cell lymphoma; LCI 2+ versus 0n = 539
Other illnesses linked to poorer lymphoma survival at 80 and over
Clinical lymphoma, myeloma & leukemia23 Sep 2026
Overall mortality
upin humans1HR 1.88
Lymphoma Epidemiology of Outcomes Comorbidity Index predicts overall mortality in humans (LCI 2+ versus 0: HR 1.88, 95% CI 1.40–2.53).
“Higher LCI predicted inferior OS (LCI 1 vs. 0: hazard ratio [HR] = 1.43 [95% CI 1.04-1.97]; LCI 2+ vs. 0: HR = 1.88 [1.40-2.53])”
HumansLarge B-cell lymphoma; LCI 2+ versus 0n = 539
Other illnesses linked to poorer lymphoma survival at 80 and over
Clinical lymphoma, myeloma & leukemia23 Sep 2026
The hazard ratio for death—a relative rate over time—was 1.43 for illness scores of one and 1.88 for two or more, versus zero.The hazard ratio for death—a relative rate over time—was 1.43 for illness scores of one and 1.88 for two or more, versus zero.